Clinical trials: Toripalimab, completed
Advanced Solid Tumor
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04914286
- Testing
- GFH018, Toripalimab
- Where
- 3 sites in Australia, China
- Volunteers
- 148 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Recurrent or Metastatic NPC
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
This is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to determine the efficacy and safety of TORIPALIMAB INJECTIO（JS001） in combination with gemcitabine/cisplatin compared with placebo in…
- Trial name
- NCT03581786
- Testing
- TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
- Where
- 32 sites in China, Singapore and 1 more
- Volunteers
- 289 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Oral Cancer, Induction Chemotherapy
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
The aim of this study is to use the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of TP, as a neoadjuvant therapy to treat the patients with locally advanced OSCC, followed with radical…
- Conditions
- Oral Cancer, Induction Chemotherapy, Programmed Cell Death 1 Inhibitor, Inductive Therapy
- Trial name
- NCT04473716
- Testing
- Toripalimab, Paclitaxcel, Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Triple-Negative Breast Cancer
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of…
- Trial name
- TORCHLIGHT (NCT04085276)
- Testing
- JS001, Nab-Paclitaxel
- Where
- 55 sites in China
- Volunteers
- 531 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced/Metastatic Solid Tumors
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04501276
- Testing
- ADG116, ADG106, anti PD1 drug
- Where
- 4 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Adagene Inc
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT07236320
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant Chemoradiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yongtao Han
Unresectable Esophageal Cancer
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT.
- Trial name
- NCT04005170
- Testing
- Toripalimab, Paclitaxel/Cisplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Mian XI
Advanced Lung Cancer
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab in patients with advanced lung cancer who have failed standard…
- Trial name
- NCT05000684
- Testing
- JS004 in combination with toripalimab
- Where
- 2 sites in China
- Volunteers
- 67 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Melanoma, Urological Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment.
- Trial name
- NCT02836795
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Anal Canal Cancer, Anal Squamous Cell Carcinoma
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent…
- Conditions
- Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer, Anal Canal Cancer Stage I
- Trial name
- NCT05060471
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
NSCLC
A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment
JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatment：a multi-center, single arm…
- Trial name
- JS001 (NCT03513666)
- Testing
- Drug intervention
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
Survival Analysis: TACE vs. Combination Therapy in HCC
This retrospective observational study aimed to assess potential improvements associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC.
- Trial name
- NCT06261138
- Testing
- Transarterial chemoembolization, Systemic treatment
- Where
- China
- Volunteers
- 279 people
- Sponsor
- Zhejiang University
Advanced Nasopharyngeal Carcinoma
A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS001sc monotherapy and combination with gemcitabine and cisplatin (GP) in patients with Advanced nasopharyngeal carcinoma.
- Trial name
- NCT05751486
- Testing
- Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Pancreatic Ductal Adenocarcinoma
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT05031494
- Testing
- YH003, Toripalimab, Nab-paclitaxel
- Where
- 2 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs).
- Trial name
- NCT06119347
- Testing
- AntiVEGF, ICIs
- Where
- China
- Volunteers
- 1,581 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
NSCLC, Stage III
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer…
- Trial name
- NCT05386888
- Testing
- GFH018, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Advanced Solid Tumors
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04169672
- Testing
- Surufatinib, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Cancer
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
The survival of the refractory CRC is dismal and therapy options are limited ，the researchers aim to investigate the efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a…
- Trial name
- NCT06011330
- Testing
- Fruquintinib combined with anti-PD-1 antibodies
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hunan Cancer Hospital